A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 80
Updated:12/27/2017
Start Date:September 22, 2017
End Date:June 2018
Contact:Lorraine M Hanley, MBA
Email:lhanley@vasularinsights.com
Phone:203-446-4953

Use our guide to learn which trials are right for you!

A Prospective, Randomized, Controlled, Multi-Center, Double Blind Study of ClariVein RES for Treatment of Venous Insufficiency Associated With Incompetent Saphenous Veins Due to Superficial Venous Reflux

VICARES is a prospective randomized, controlled, multi-center, double blind study treating
venous insufficiency associated with incompetent saphenous veins with 1% and 3% Sodium
Tetradecyl Sulfate (STS) solution utilizing the ClariVein system.

Approximately 50 subjects diagnosed with an incompetent saphenous vein will be randomized to
either 1% STS or 3% STS solution delivered by the ClariVein system under ultrasound guidance.

Study duration for individual study patients, including follow-up visits, is anticipated to
be approximately 16 weeks.

Inclusion Criteria:

1. Adult patient with incompetent saphenous vein

2. Saphenous vein reflux > 500ms (0.5s), as measured by duplex ultrasound

3. One or more of patient reported symptoms related to the target vein: i.e., heaviness,
achiness, swelling, throbbing or itching.

4. Candidate for endovenous procedure

Exclusion Criteria:

1. Arterial insufficiency demonstrated by a history of peripheral arterial disease (PAD)
that would preclude the wearing of compression stockings

2. Absence of a palpable pulse at posterior tibial or dorsalis pedis and an
Ankle-Brachial Index (ABI) <0.6

3. Multi-segmental axial deep venous reflux in at least two contiguous venous segments
(e.g., femoral and popliteal) in the ipsilateral extremity

4. Previous surgical or endovenous procedure in the treatment section of the target vein

5. Previous superficial thrombophlebitis of the target saphenous vein with scarring in
the treatment section

6. Pregnant or breastfeeding

7. Known sensitivity or allergic response to Sodium Tetradecyl Sulfate (STS)

8. Known high risk of thrombosis

9. Known history of deep vein thrombus (DVT) or pulmonary embolism (PE), known history of
acute superficial vein thrombus, known hypercoagulable condition, post thrombotic
syndrome

10. Known history of anaphylaxis or presence of multiple severe allergies
We found this trial at
5
sites
100 Camp Street
Hyannis, Massachusetts 02601
Principal Investigator: Daniel Gorin, MD
Phone: 508-775-1984
?
mi
from
Hyannis, MA
Click here to add this to my saved trials
Bellevue, Washington 98004
Principal Investigator: Kathleen Gibson, MD
Phone: 425-453-1772
?
mi
from
Bellevue, WA
Click here to add this to my saved trials
85 Old Kings Highway North
Darien, Connecticut 06820
Principal Investigator: Paul J Gagne, MD
Phone: 203-956-6800
?
mi
from
Darien, CT
Click here to add this to my saved trials
350 Engle Street
Englewood, New Jersey 07631
Principal Investigator: Steven Elias, MD
Phone: 201-894-3852
?
mi
from
Englewood, NJ
Click here to add this to my saved trials
Frederick, Maryland 21702
Principal Investigator: Paul McNeill, MD
Phone: 301-695-8346
?
mi
from
Frederick, MD
Click here to add this to my saved trials